We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27.00 | 9.31% | 317.00 | 310.00 | 324.00 | 320.00 | 305.00 | 305.00 | 16,746 | 08:37:32 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.73 | 406.77M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 16/5/2016 18:30 | There's a new video interview on ProactiveInvestors with Doug Doerfler (MaxCyte CEO) which is well worth a look, he seems very excited about their CARMA technology platform, the first product (to showcase the technology) is effective in Mouse and should be ready for the clinic (platinum resistant ovarian cancer) in H2/2017 | timbo003 | |
| 04/5/2016 20:14 | There's a useful article over on Proactiveinvestors (dated May 2nd) which explains why Maxcyte (a US based company) went for an AIM IPO rather than a Nasdaq IPO. | timbo003 | |
| 04/4/2016 09:42 | Thanks oshy, that was very helpful. | timbo003 | |
| 04/4/2016 09:19 | Morning, Short TV clip on MaxCyte: www.fmp-tv.co.uk/com | oshy92 | |
| 29/3/2016 18:49 | That was a good start to life on Aim, up circa 10% with only three trades (total 2,407 shares traded). All a bit academic for me, as this needs to be a three year hold for the tax breaks. | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
